|
|
|
|
Hematological malignancies
SuperGen Announces Results From Combination Study in CLL Published ... 14 Mar 2006
PR Newswire (press release), ...company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. ...
Thalidomide shows promise for ALS Mar 11, 2006
Monsters and Critics.com, Pharmion and Celgene are jointly developing thalidomide for a number of other indications, including solid tumor and hematological malignancies, but Pharmion ...
PCR-ELISA Helps Spot Invasive Aspergillosis Mar 9, 2006
Cancerpage.com, ...surveillance, PCR-ELISA "may improve the rates of early diagnosis of invasive aspergillosis and the management of patients with hematological malignancies.".
Displaced doctor brings music and medicine to Shreveport Mar 9, 2006
Shreveport Times, In October Ballester was hired as director of clinical research for the Hematological Malignancies and Bone Marrow Transplant Program. ...
Loss up, revenue down at Avalon Mar 8, 2006
Washington Business Journal, ...early-stage study to determine whether the experimental drug is safe when given to adult patients with advanced hematological malignancies, including leukemia ...
Millennium Pharmaceuticals: more Velcade ventures Mar 7, 2006
Pharmaceutical Business Review ...indicative of Millennium's commitment to the global development of Velcade, which is also being studied in numerous solid tumors and hematological malignancies ...
Avalon Pharmaceuticals Reports Fourth Quarter and Full Year 2005 ... Mar 7, 2006
PR Newswire (press release), ...dose-escalation study for the evaluation of the safety and tolerability of AVN944 in adult patients with advanced hematological malignancies including those ...
PHARMION CORPORATION ANNOUNCES 2005 FINANCIAL Feb 22, 2006
ITNews, MGCD0103 is currently the subject of several Phase I studies in hematological malignancies and solid tumors, as well as a Phase I/II study in acute myelogenous ...
Stem Cell Therapy For Heart Attack Found To Be Ineffective Mar 1, 2006
MedIndia, ...are being published, highlighting the promise of stem cell therapy in the treatment of neurodegenerative disorders, hematological malignancies, injury, and ...
Umbilical Cord Blood Transplantation an Excellent Alternative to ... Feb 21, 2006
DG News The study was intended to evaluate the use of cord blood transplantation in children with hematological malignancies, metabolic disorders or immune ...
Gloucester Pharmaceuticals Reports on Phase 2 Clinical Study ... Mar 1, 2006
Business Wire (press release), We've already generated positive data in clinical trials of depsipeptide for the treatment of certain hematological malignancies, and are pleased that these ...
Biotech's Mid Caps Post Solid Gain in February Mar 1, 2006
PR Newswire (press release), ...(up 28%) reported that it had completed a three week dosing regimen in its Phase I clinical trial of AVN944 in patients with advanced hematological malignancies ...
SuperGen Reports 2005 Fourth Quarter and Year-End Financial ... Feb 23, 2006
PR Newswire (press release), MGI PHARMA sponsored a corporate symposium titled Modulation of Methylation Status: Innovation in the Treatment of Hematological Malignancies, which was ...
Recruitment Temporarily Suspended in an International Phase III ... Feb 12, 2006
PR Newswire (press release), Avastin is also being evaluated in earlier stage trials as a potential therapy in a variety of solid tumor cancers and hematological malignancies. ...
SuperGen Announces Withdrawal of Orathecin Marketing Authorization ... Jan 20, 2006
PharmaLive.com (press release), ...company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. ...
Avalon Pharmaceuticals Initiates AVN944 Phase I Clinical Trial in ... Jan 9, 2006
PR Newswire (press release), ...of small molecule therapeutics, today announced the initiation of a Phase I clinical trial of AVN944 in patients with advanced hematological malignancies. ...
Calcium Receptor Vital For Stem Cell Migration to Bone Marrow Jan 14, 2006
MedIndia, Bone marrow transplantation is a life saving treatment option for a number of people suffering from hematological malignancies and other condition such as ...
Avalon begins Phase I trial for cancer drug Jan 9, 2006
Washington Business Journal, The first round of human testing will evaluate the drug's safety and tolerability in adult patients with advanced hematological malignancies, including leukemia ...
Pluristem Announces Advanced Engineered Cell Graft to Improve ... Jan 12, 2006
Genetic Engineering News, Although the field of stem cell technology holds great promise, the transplantation of HSC into patients with hematological malignancies remains the only ...
Pluristem develops alternative to bone marrow transplant Jan 13, 2006
Pharmaceutical Business Review ...of stem cell technology holds great promise, the transplantation of hematopoietic stem cells (HSCs) into patients with hematological malignancies remains the ...
INNOVIVE Pharmaceuticals Licenses Potent Dual Bcr-Abl/Lyn Kinase ... Jan 5, 2006
Business Wire (press release), ...in the development, manufacture, and sale of ethical drugs for the treatment of urological, inflammatory and allergic diseases and hematological malignancies. ...
Stem Cell Research - Changing Wishes to Possibilities and ... Jan 6, 2006
MedIndia, ...neurological disorders such as ALS and stroke’ (in animal models), the ‘Role of stem cell transplantation in hematological malignancies’ (chronic myeloid ...
Keryx Biopharmaceuticals, Inc. Commences Phase II, Multi-Center ... Jan 3, 2006
Yahoo! News (press release) ...to conduct this important clinical program." Dr. Henderson added, "We believe that KRX-0401 may be very effective in hematological malignancies because they ...
Switching Fluoroquinolones in Patients with Neutropenia May ... Dec 19, 2005
DG News The study included all patients undergoing chemotherapy for hematological malignancies with an expected duration of neutropenia of at least 5 days. ...
Dacogen(TM) (Decitabine) Injection Data Presented at American ... Dec 12, 2005
Genetic Engineering News, MGI PHARMA sponsored a Corporate Friday symposium titled Modulation of Methylation Status: Innovation in the Treatment of Hematological Malignancies, which was ...
Cyclacel and Xcyte Therapies Combine to Form International ... Dec 15, 2005
PharmaLive.com (press release), ...available cyclin dependent kinase inhibitor, in Phase II clinical trials for the treatment of non-small cell lung cancer and B-cell hematological malignancies. ...
Cyclacel and Xcyte Therapies Combine to Form International ... Dec 15, 2005
Finanzen.net, ...available cyclin dependent kinase inhibitor, in Phase IIclinical trials for the treatment of non-small cell lung cancer andB-cell hematological malignancies. ...
Cougar Biotechnology Announces Presentation of Positive ... Dec 13, 2005
Genetic Engineering News, We look forward to continued clinical development of the drug in the hematological malignancies." Alan H. Auerbach, Chief Executive Officer and President of ...
Dacogen(TM) (Decitabine) Injection Complete Response Accepted for ... Dec 15, 2005
Genetic Engineering News, ...company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. ...
CuraGen and TopoTarget Announce Presentation of PXD101 Phase I ... Dec 12, 2005
PharmaLive.com (press release), ...are believed to play a role in a wide range of solid tumors, such as breast, colon, lung and ovarian cancers, and hematological malignancies, such as lymphoma ...
New Data Suggest GM-CSF May Enhance Efficacy of Rituximab in ... Dec 12, 2005
PR Newswire (press release), ...analysis of the blood cells found in the biopsy tissue help the pathologist to distinguish NHL from Hodgkin's disease and other hematological malignancies. ...
(PRN) - ATCT Announce the Addition of Michael Nurse to the Board ... Dec 8, 2005
Bolsamania.com, ...[+]. (PRN) - Clinical Data on Vidaza(R) (Azacitidine for Injectable Suspension) in Higher-Risk MDS, AML and Other Hematological Malignancies to be Presented at ...
AnorMED announces 73 percent of cancer patients who failed prior ... Dec 12, 2005
PR Newswire (press release), ALC15 after autologous stem cell transplantation is an independent, prognostic indicator for survival in multiple hematological malignancies (Leukemia and ...
MethylGene Reports Encouraging Preliminary Clinical Results for ... Dec 8, 2005
CCNMatthews (press release), MGCD0103 is currently in Phase I dose-escalation monotherapy trials against solid tumours and hematological malignancies and also in a Phase I/II combination ...
Clinical Data on Vidaza (Azacitidine for Injectable Suspension) in ... Dec 9, 2005
PharmaLive.com (press release), BOULDER, Colo., December 08, 2005 /PRNewswire-FirstCall/ -- Pharmion Corporation reported today that data from several Vidaza(R) studies will be presented at ...
Cyclacel applies for Aurora Kinase inhibitor IND Nov 10, 2005
in-PharmaTechnologist, ...available Cyclin Dependent Kinase inhibitor, in Phase II clinical trials for the treatment of non-small cell lung cancer and B-cell hematological malignancies. ...
Burrill & Company Advises Danisco A/S on Divestiture of Genencor ... Nov 10, 2005
PR Newswire (press release), LONDON: CAT) . Genencor's immunotoxin program consists of GCR-3888 and GCR-8015, both of which target hematological malignancies. GCR ...
GPC Biotech Announces Clearance From German Regulatory Authority ... Nov 9, 2005
Market Wire (press release) He is a world-renowned expert in the treatment of hematological malignancies and has worked with GPC Biotech for several years on the development of 1D09C3.". ...
Doctor gambles on a new challenge Nov 6, 2005
Boston Globe, ...when the nascent center in Las Vegas began to form and its director, Dr. Nicholas Vogelzang, began courting him to be chief of hematological malignancies. ...
Cambridge Antibody Technology Acquires Oncology Product Candidates ... Oct 31, 2005
Yahoo! News (press release) Genencor licensed the candidates for hematological malignancies and entered into a cooperative research and development agreement (CRADA) with the NIH, which ...
Amphora to Present Posters on Promising Results From AKT and ... Nov 8, 2005
PharmaLive.com (press release), ...for the Treatment of Hematological Malignancies and Solid Tumors. over a broad panel of 96 enzymes. These inhibitors have been rapidly. Title: Is One Enough? ...
Addition of Pixantrone to Rituxan Therapy Significantly Prolongs ... Nov 9, 2005
PharmaLive.com (press release), Pixantrone is an investigational agent under development for the potential treatment of various hematological malignancies, solid tumors, and immunological ...
Amphora to Present Posters on Promising Results From AKT and ... Nov 8, 2005
Biotech Intelligence (press release), Title: Multi-Targeted Tyrosine Kinase Inhibitors of FLT3 + cKIT + PDGFR for the Treatment of Hematological Malignancies and Solid Tumors. Poster A264. ...
Amphora to Present Posters on Promising Results From AKT and ... Nov 8, 2005
PR Newswire (press release), 7.30 pm Poster Session A Title: Multi-Targeted Tyrosine Kinase Inhibitors of FLT3 + cKIT + PDGFR for the Treatment of Hematological Malignancies and Solid ...
MethylGene Announces Third Quarter 2005 Results Nov 1, 2005
Business Wire (press release), America. MGCD0103 is currently in Phase I dose-escalation monotherapy trials against solid tumours and hematological malignancies. ...
Danisco sells part of Genencor's Health Care product portfolio Nov 1, 2005
Food Ingredients First (press release), 1 August 2005, Genencor continued the development activities for GCR-8015 (pre-clinical) and GCR-3888 (clinical), two compounds for hematological malignancies. ...
Cancer treatment affects fertility Nov 5, 2005
myDNA.com, ...showcased at the 13th European Cancer Conference (ECCO) have examined the effect of chemotherapy and radiotherapy for hematological malignancies on subsequent ...
ImmunoGen, Inc. Reports First Quarter Fiscal Year 2006 Financial ... Nov 3, 2005
Genetic Engineering News, ...targets the CD56 antigen found on small-cell lung cancers (SCLC), other cancers of neuroendocrine origin, and certain hematological malignancies including many ...
Conference examines role of chromosome changes in cancer Oct 28, 2005
EurekAlert (press release), 11:00 James Downing, MD, Scientific Director and Chair of Pathology; Co-Leader of the Hematological Malignancies Program and Director of the Molecular ...
Pharmion Reports Third Quarter 2005 EPS of $0.27, Nine Month EPS ... Oct 25, 2005
PR Newswire (press release), ...over 25 Company- and investigator-sponsored clinical studies examining the use of Vidaza in the treatment of MDS, other hematological malignancies and solid ...
SuperGen to Present at CE Unterberg, Towbin Life Sciences ... Oct 21, 2005
PR Newswire (press release), ...company dedicated to the acquisition, rapid development and commercialization of therapies for solid tumors, hematological malignancies and blood disorders. ...
Although hematological malignancies are a form of cancer, they are generally treated by specialists in hematology, although in many hospitals oncology specialists also manage these diseases. ("Hematology/Oncology" is a single subspecialty of Internal Medicine; there are also surgical and radiation oncologists.)
Hematological malignancies are the types of cancer that affect blood, bone marrow and lymph nodes. As the three are intimately connected through the immune system, a disease affecting one of the three will often affect the others as well: although lymphoma is technically a disease of the lymph nodes, it often spreads to the bone marrow, affecting the blood and occasionally producing a paraprotein.
Chromosomal translocations are a common cause of these diseases, while this is uncommon in solid tumors. This leads to a different approach in diagnosis and treatment of hematological malignancies.
|
|
|
